Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment

Matteo Caporro
Giulio Disanto
Claudio Gobbi
Chiara Zecca

Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland

Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing–remitting multiple sclerosis. Several clinical trials have shown consistent and sustained efficacy of glatiramer acetate 20 mg subcutaneously daily in reducing relapses and new demyelinating lesions on magnetic resonance imaging in patients with relapsing–remitting multiple sclerosis, as well as comparable efficacy to high-dose interferon beta. Some preclinical and clinical data suggest a neuroprotective role for glatiramer acetate in multiple sclerosis. Glatiramer acetate is associated with a relatively favorable side-effect profile, and importantly this was confirmed also during long-term use. Glatiramer acetate is the only multiple sclerosis treatment compound that has gained the US Food and Drug Administration pregnancy category B. All these data support its current use as a first-line treatment option for patients with clinical isolated syndrome or relapsing–remitting multiple sclerosis. More recent data have shown that high-dose glatiramer acetate (ie, 40 mg) given three times weekly is effective, safe, and well tolerated in the treatment of relapsing–remitting multiple sclerosis, prompting the approval of this dosage in the US in early 2014. This high-dose, lower-frequency glatiramer acetate might represent a new, more convenient regimen of administration, and this might enhance patients’ adherence to the treatment, crucial for optimal disease control.

Keywords: glatiramer acetate, disease modifying treatment, efficacy, safety

Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disease involving the white and gray matter of the central nervous system (CNS), causing neurological dysfunction. It affects predominantly females, and has a prevalence varying from five to 80 per 100,000 persons worldwide. It is thought to be a multifactorial disease resulting from an autoimmune reaction to self-antigens in genetically predisposed individuals, and probably involving additionally several environmental factors, such as vitamin D deficiency, sun exposure, smoking, and infections. Evidence for a concomitant neurodegenerative component has been highlighted to be present already at disease onset; however, this prevails in the later phases of the disease.

Multifocal localized inflammation of the CNS leading to demyelination, axonal damage, and astrocytosis pathologically characterizes the disease and causes impaired nerve conduction, leading to MS symptoms commonly involving sensory, motor, visual, balance, sphincteric, and cognitive functions, as well as fatigue.
Relapsing–remitting (RR) is the most common (80%–85%) MS subtype, characterized by flares and remissions.6,7 The first MS relapse is currently referred to as clinically isolated syndrome (CIS), corresponding to a typical clinical and paraclinical early RRMS picture that cannot however fulfill current MS diagnostic criteria.8 Approximately 60%–70% of patients with RRMS evolve to secondary progressive MS over time, and around 10% of patients can be classified as having a primary progressive or progressive relapsing course.

Though incurable, MS is currently treatable, with the aim of delaying as much as possible disability progression that may derive principally from unrecovered relapses and progressive neurological deterioration. To this end, several immunomodulating, immunosuppressive, and immunobiological agents have been developed to control inflammatory activity, prevent relapses, and possibly delay disability progression, particularly in the early phase of the disease.

Glatiramer acetate (GA; Copaxone®; Teva Pharmaceutical Industries, Petah Tikva, Israel) and beta-interferons (IFNβs) have been traditionally considered first-line treatments of RRMS, and represent the cornerstone in MS therapy.9 Until recently, these two drug types were the only immunomodulatory therapies available for the treatment of RRMS. However, these drugs are not always sufficiently efficacious to suppress inflammatory activity in all MS patients. Moreover, they may not be well tolerated due to side effects or frequent injections, which sometimes preclude adequate adherence.10 The advent of second-line drugs, such as natalizumab,11 fingolimod,12 teriflunomide,13 and dimethyl fumarate,14 as well as alemtuzumab15 in some countries, is promising both for possible higher anti-inflammatory efficacy and a more convenient way of administration (ie, either intravenous injections or oral). These advantages have, however, the price of a variable but overall less favorable safety and side-effect profile.16 Nevertheless, the approval of these new compounds changed the MS therapeutic landscape and the first-line drug-decision process in a newly diagnosed MS patient.

This paper reviews relevant data concerning the mechanism of action, efficacy, and safety of GA administered at the licensed (20 mg daily) dose, summarizes more recent data concerning the administration of GA at higher doses with lower frequency, and aims to define its current role as a treatment option in MS.

PubMed was searched for abstracts using the terms “glatiramer acetate AND multiple sclerosis” and “glatiramer acetate AND adherence”. Only articles written in English were considered, and there was no time-period restriction. The references of the resulting studies were used to identify additional articles to be included in the review (Table 1).

Glatiramer acetate
GA (Copaxone) is a synthetic amino acid polymer analog of myelin basic protein (MBP), an antigen thought to be involved in the pathogenesis of MS.17–21 It consists of a standardized combination of four amino acids (L-alanine, L-glutamic acid, L-lysine and L-tyrosine) randomly combined to form a polymer with an average length of 40–100 amino acids.17–20

It has been empirically found to suppress autoimmune encephalomyelitis in mice,22 possibly due to a displacement of immune cells targeting native myelin components. Clinical results consistent with this rationale have also been shown in humans, leading to its licensing for MS treatment in 1997 in the US and 2000 in Europe. Initially, GA was approved as first-line treatment in RRMS at a dose of 20 mg subcutaneous (SC) injection daily. More recently, further approval was obtained for the treatment of CIS patients.23

Mechanism of action
It is believed that GA has a multifaceted mechanism of action, involving both immunomodulation and neuroprotection (Figure 1). It is basically an immunomodulator capable of modifying the immune responses that drive MS pathogenesis.17–20,24 It binds to major histocompatibility complex (MHC) class II molecules on MBP-specific antigen-presenting cells, preventing MBP itself from binding to and stimulating these cells.18,20,24 A body of preclinical and clinical data support a role of GA in inducing a T-helper (Th)-1 to Th2-cell phenotype shift. In other words, GA-reactive T cells predominantly secrete anti-inflammatory cytokines, such as IL-1, IL-4, and IL-10, characterizing Th2 regulatory cells instead of typical Th1, and proinflammatory cytokines, such as IL-2 and IL-12.18,20,24 It has to be underlined that GA per se is not able to penetrate the CNS blood–brain barrier. Its immunomodulatory function is carried out by peripheral GA-induced Th2 cells that enter the CNS, recognize myelin antigens, and are thus reactivated, ultimately reducing inflammation associated with MS.24–26 This mechanism of action is known as “bystander suppression”.27

In addition, several studies have suggested further effects on the immune system mediated by GA.17,24 GA induces T-regulatory cells, such as CD4+, CD8+, and CD4+CD25+ T cells, while it downregulates Th17 cells that have been associated with MS disease activity. Moreover, GA drives monocytes, dendritic cells, and microglias to preferential anti-inflammatory responses.24,25,28–34
### Table 1 Reviewed studies

<table>
<thead>
<tr>
<th>Article</th>
<th>Patients</th>
<th>Treatment arm</th>
<th>Comparison</th>
<th>Length of follow-up</th>
<th>Main outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pivotal trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bornstein et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=25)</td>
<td>Placebo (n=23)</td>
<td>2 years</td>
<td>No relapse in 56% of GA-treated subjects versus 26% in placebo (P=0.045)</td>
</tr>
<tr>
<td>Johnson et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=125)</td>
<td>Placebo (n=126)</td>
<td>2 years</td>
<td>29% reduction in relapse rate compared to placebo (P=0.007)</td>
</tr>
<tr>
<td>Comi et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=119)</td>
<td>Placebo (n=120)</td>
<td>9 months</td>
<td>Reduced number of GdE lesions compared to placebo (P=0.003)</td>
</tr>
<tr>
<td>Comi et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>CIS</td>
<td>GA 20 mg/day SC (n=243)</td>
<td>Placebo (n=238)</td>
<td>Up to 36 months</td>
<td>45% reduced risk of conversion to CDMS compared to placebo (HR 0.55, 95% CI 0.40–0.77; P=0.0005)</td>
</tr>
<tr>
<td><strong>Extension studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=99) since study initiation</td>
<td>Placebo (n=104) since study initiation</td>
<td>Johnson et al&lt;sup&gt;39&lt;/sup&gt; extended for additional 1–11 months</td>
<td>32% reduction in relapse rate compared to placebo (P=0.002)</td>
</tr>
<tr>
<td>Johnson et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=83) for 6 years since study initiation</td>
<td>GA 20 mg/day SC after placebo for 30 months (n=86, end of 6th year)</td>
<td>Johnson et al&lt;sup&gt;41&lt;/sup&gt; extended to 6 years</td>
<td>No difference in relapse rate between the two groups after placebo-treated patients' switch to GA</td>
</tr>
<tr>
<td>Johnson et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=72) for 8 years since study initiation</td>
<td>GA 20 mg/day SC after placebo for 30 months (n=70, end of 8th year)</td>
<td>Johnson et al&lt;sup&gt;42&lt;/sup&gt; extended to 8 years</td>
<td>No difference in relapse rate between the two groups after placebo-treated patients' switch to GA</td>
</tr>
<tr>
<td>Ford et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>RRMS</td>
<td>At least one dose of GA 20 mg/day SC (n=232)</td>
<td>–</td>
<td>Johnson et al&lt;sup&gt;43&lt;/sup&gt; extended to 10 years</td>
<td>Decreased relapse rate from 1.18/year prestudy to approximately 1/5 years during study</td>
</tr>
<tr>
<td>Ford et al&lt;sup&gt;44&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=100, end of 15th year) since study initiation</td>
<td>–</td>
<td>Johnson et al&lt;sup&gt;44&lt;/sup&gt; extended to 15 years</td>
<td>Decreased relapse rate from 1.12/year prestudy to 0.25/year during study</td>
</tr>
<tr>
<td>Wolinsky et al&lt;sup&gt;45&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=111) since study initiation</td>
<td>GA 20 mg/day SC after placebo for 9 months (n=113)</td>
<td>Comi et al&lt;sup&gt;23&lt;/sup&gt; extended for additional 9 months</td>
<td>54% reduction in mean number of GdE lesions in patients switching to GA</td>
</tr>
<tr>
<td>Rovaris et al&lt;sup&gt;46&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 20 mg/day SC (n=73) since study initiation</td>
<td>GA or other/no treatment after placebo for 9 months (n=69)</td>
<td>Comi et al&lt;sup&gt;23&lt;/sup&gt; extended to a mean of 5.8 years</td>
<td>No difference in MRI measures between the two groups</td>
</tr>
<tr>
<td><strong>Head-to-head trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mikol et al&lt;sup&gt;47&lt;/sup&gt;</td>
<td>RRMS</td>
<td>IFNβ-1a 44 μg 3 times/week SC (n=386)</td>
<td>GA 20 mg/day SC (n=378)</td>
<td>96 weeks</td>
<td>No difference in time to first relapse (HR 0.94, 95% CI 0.74–1.21; P=0.64) between the two groups</td>
</tr>
<tr>
<td>O'Connor et al&lt;sup&gt;49&lt;/sup&gt;</td>
<td>RRMS</td>
<td>IFNβ-1b 250 μg/2 days SC (n=888) and 500 μg/2 days SC (n=887)</td>
<td>GA 20 mg/day SC (n=445)</td>
<td>2.0–3.5 years</td>
<td>No difference in relapse risk (P=0.48 and P=0.74) between the groups</td>
</tr>
<tr>
<td>Cadavid et al&lt;sup&gt;50&lt;/sup&gt;</td>
<td>RRMS or CIS</td>
<td>IFNβ-1b 250 μg/2 days SC (n=36)</td>
<td>GA 20 mg/day SC (n=39)</td>
<td>Up to 2 years</td>
<td>No significant difference in combined active lesions (P=0.58) between the two groups</td>
</tr>
<tr>
<td><strong>Studies with high-dose GA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen et al&lt;sup&gt;51&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 40 mg/day SC (n=46)</td>
<td>GA 20 mg/day SC (n=44)</td>
<td>9 months</td>
<td>Trend to lower number of GdE lesions in the 40 mg group (38% reduction, P=0.089)</td>
</tr>
<tr>
<td>Comi et al&lt;sup&gt;52&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 40 mg/day SC (n=569)</td>
<td>GA 20 mg/day SC (n=586)</td>
<td>12 months</td>
<td>No difference in relapse rate between the two groups (P=0.49)</td>
</tr>
<tr>
<td>Khan et al&lt;sup&gt;53&lt;/sup&gt;</td>
<td>RRMS</td>
<td>GA 40 mg 3 times/week SC (n=943)</td>
<td>Placebo (n=461)</td>
<td>12 months</td>
<td>34% reduction of annual relapse rate compared to placebo (P&lt;0.0001)</td>
</tr>
</tbody>
</table>

**Abbreviations:** RRMS, relapsing-remitting multiple sclerosis; CIS, clinically isolated syndrome; CDMS, clinically definite multiple sclerosis; GA, glatiramer acetate; SC, subcutaneously; HR, hazard ratio; CI, confidence interval; GdE, gadolinium-enhancing; iFNβ, interferon beta; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging.
Finally, GA seems to induce neuroprotective and/or neuroregenerative effects at the preclinical level.\textsuperscript{17,18,24,25} For instance, it increases neurotrophic factors like brain-derived neurotrophic factor, involved in neuronal and glial cell survival, and may mediate neuroprotection. There is also evidence that GA induces remyelination and enhances neurogenesis.\textsuperscript{17,18,21,24,25}

The majority of patients treated with GA develop GA-reactive IgG antibodies. However, these do not appear to be related to clinical or radiological clinical course measures of efficacy.\textsuperscript{35–37}

**Clinical efficacy: data from clinical trials**

**Pivotal trials**

Pivotal trials have shown consistent efficacy of GA in the treatment of RRMS patients. The first study assessing the efficacy of GA in RRMS was published more than 25 years ago.\textsuperscript{38} It was a double-blind, randomized, placebo-controlled pilot trial involving 50 RRMS patients who were treated either with daily GA 20 mg or daily placebo over 2 years. Twenty-six percent of placebo- and 56% of GA-treated patients experienced no relapses over the study period ($P=0.045$). Among less disabled patients (Kurtzke disability score 0–2), those taking GA improved (+1.2 Kurtzke units), while placebo-treated patients worsened (−0.5 Kurtzke units, $P=0.012$). In contrast, more disabled patients in both groups showed an increase in Kurtzke disability score. Limited by the small sample size, this pivotal trial provided the first clinical evidence for a role of GA in the treatment of RRMS. A number of subsequent larger multicenter trials confirmed these results.

The first large Phase III double-blind, placebo-controlled study included 251 RRMS subjects 18–45 years old, with an Expanded Disability Status Scale (EDSS) score of 0–5.0, a history of at least two relapses in the 2 years prior to study entry, and a disease duration of at least 1 year. Participants were
randomized to receive GA or placebo by daily SC injection for 2 years, with a reduction of 29% in the annualized relapse rate (ARR; primary end point) in favor of the GA group (0.59 versus 0.84, respectively; \( P=0.0007 \)). Among secondary clinical outcomes, median time to first relapse from baseline and the proportion of relapse-free patients over 2 years showed a trend favoring GA over placebo (287 versus 198 days, \( P=0.097; 33.6\% \) versus 27.0\%, \( P=0.098 \); respectively). Overall, parameters of disability change also favored GA over placebo (EDSS change from baseline –0.05 versus 0.21, \( P=0.023 \)), though the proportion of patients who were free from disability progression was similar between groups (78.4\% versus 75.4\%, not significant). The main limitation of this trial was the absence of magnetic resonance imaging (MRI) monitoring.

A pivotal GA study by Johnson et al was followed by a prospective, open-label study replicating the benefits of early versus delayed GA at 3, 6 and 8 years. Further 10-year extension data were obtained from 47\% of the original cohort, and showed that continuous GA treatment led to more than 80\% decline in relapse rate (from 1.18 relapses/year prestudy to one relapse/5 years), with no significant disability progression, evaluated using the EDSS score. Recently, data concerning 15-year extension were published. Of the initially randomized subjects, 43\% were still on GA treatment, and had received only this immunomodulator during the disease course. Of those, two-thirds had not reached secondary progression, 57\% had stable or improved EDSS, and 82\% of patients could still walk. The comparator cohort that had interrupted GA obtained fairly good results as well; however, the mean disease duration in these patients was much shorter (13 versus 22 years).

The clinical efficacy of GA was replicated in a European/Canadian trial involving 239 RRMS subjects, and extended results toward a benefit on MRI disease activity. Main inclusion criteria were age between 18 and 50 years, a disease duration of at least 1 year, an EDSS score up to 5.0, and documented disease activity (at least one relapse in the preceding 2 years, and at least one gadolinium-enhanced [GdE] lesion on their screening brain MRI). Patients were randomized to either daily injections of GA 20 mg or placebo and treated for 9 months, and were followed with monthly brain MRIs. GA-treated patients showed a significant reduction in total GdE lesions (primary end point –10.8 versus –18.0, \( P=0.003 \)), number and volume of new \( T_2 \) lesions, and brain-atrophy progression, as well as clinical efficacy measured by reduction of mean relapse rate. Interestingly, the treatment effect of GA on the mean number of GdE lesions per patient per month, as well as mean number of relapses per patient, consistently appeared only from month 6 after GA start. However, the short duration of the study prevented assessment of treatment effects on disability progression, especially in light of the delayed onset of GA action.

In the 9-month, open-label phase of the European/Canadian study involving 94\% of the original cohort, the effect of GA treatment was sustained: a 54\% reduction in the mean number of GdE lesions for those switching from placebo to GA and a further 24.6\% reduction for those remaining on GA were observed. A 5.8-year extension phase involving 63.4\% of the original cohort showed that 66\% of the patients were still on GA and had the highest relapse-free period, compared either to IFN switchers or to untreated patients (3.5 versus 1.3 versus 2.9, respectively). No significant differences for any MRI parameters were found at 5 years between originally GA- or placebo-treated subjects. However, the proportion of patients not requiring walking aids was lower in the first group (\( P=0.034 \)), suggesting that an earlier initiation of GA might have a favorable impact on long-term disease evolution.

In conclusion, between the late 1980s and early 2000s, the results of three pivotal trials were published, which consistently assessed the efficacy of GA in the treatment of patients with RRMS, showing an approximately 30\% reduction in relapse rate and consistent benefits on MRI for surrogates of disease activity compared to placebo. Open-label extension studies consistently showed a sustained efficacy of GA up to 15 years in a subgroup of patients participating in pivotal trials, though these were limited by several factors, including absence of a placebo arm and positive selection of responders.

**CIS trial**

GA has been recently labeled for CIS based on the favorable results of the PreCISE (Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting with Clinically Isolated Syndrome) trial. This involved 481 subjects presenting with a monofocal CIS and two or more \( T_2 \) brain lesions (>6 mm), that were randomly assigned to either SC GA 20 mg per day or placebo. A significant delay in conversion to clinically definite MS (722 versus 336 days in the treatment versus placebo groups, \( P=0.0005 \)), as well as consistent benefits on radiological parameters (number/volume of new \( T_2 \) lesions, and hypointense lesions) were observed after approximately 2.4 years of treatment. The study included only a restricted subgroup of CIS subjects, and did not provide information concerning the impact of GA on disability progression. In conclusion, the PreCISE trial provided substantial information in favor of the effectiveness of GA in the treatment of early forms of MS.
Head-to-head trials

Three head-to-head trials\textsuperscript{48-50} assessed the efficacy of GA compared to high-dose IFNs. REGARD\textsuperscript{49} (REbif vs Glatiramer Acetate in Relapsing MS Disease) was a randomized, open-label trial comparing SC IFN-\(\text{b}\)-1a 44 \(\mu\)g three times per week (Rebif\textsuperscript{50}; EMD Millipore, Billerica, MA, USA) to daily SC GA 20 mg in 764 RRMS patients. Main inclusion criteria were 18–60 years of age, EDSS score between 0 and 5.5, and at least one relapse in the year prior to study entry. After 96 weeks, there were no differences between the two treatment groups in the time to relapse (primary outcome, \(P=0.64\)) or in the number or volume of active \(T_2\) lesion load on MRI. However, the IFN group showed significantly fewer GdE lesions, and the GA-group had less pronounced brain-volume loss (1.073% versus 1.24%, \(P=0.018\)). The main limitations of the study were a lack of patient blinding to treatment (although the assessor was blinded) and a low on-study relapse rate, which could have prevented the capturing of differences between the two active compounds.

BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) was a large randomized trial\textsuperscript{50} involving 2,244 RRMS patients randomized to either 250 \(\mu\)g SC or 500 IFN-\(\text{b}\)-1b (Betaseron\textsuperscript{50}; Bayer, Leverkusen, Germany) every other day or daily 20 mg GA SC over a minimum of 2 years. Main inclusion criteria were 18–55 years of age, EDSS score between 0 and 5.0, and at least one relapse in the year prior to study entry. Results demonstrated no statistically significant differences in the ARR (0.33, 0.36, and 0.34, respectively), disability progression measured by EDSS, the majority of MRI-monitoring parameters (GdE lesions, \(T_1\) lesions, normalized brain volume) among groups. Partial blinding was a major limitation.

The BECOME (Betaseron vs Copaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints) study\textsuperscript{50} compared primarily radiological efficacy of SC IFN-\(\text{b}\)-1b 250 \(\mu\)g every other day and daily SC 20 mg GA over 2 years in 75 RRMS and CIS patients. Main inclusion criteria were 18–55 years of age and EDSS score <5.5. The study was performed using a 3 T MRI machine and administering triple-dose Gd combined with delayed imaging, which is known to more than double lesion detection compared to standard techniques. Treatment arms showed similar results in the number of combined active lesions (overall GdE plus new nonenhancing fluid-attenuated inversion-recovery lesions) per patient per scan at year 1, obtained by monthly brain MRI monitoring. The main limitations of this study were the relatively small sample size, lack of patient blinding, and the monocentric design.

It has to be underlined that in all these head-to-head trials, the on-study relapse rate was much lower than the rates reported in the pivotal trials (0.29–0.34 in head-to-head studies versus 0.59 in the Johnson et al trial),\textsuperscript{50} mainly reflecting a change in study populations over two decades. Increasing treatment options and changes in MS diagnostic criteria probably account for this phenomenon.

Among the novel therapeutic compounds for MS, only the Phase III CONFIRM (Comparator and an Oral Fumarate in Relapsing–Remitting Multiple Sclerosis) trial\textsuperscript{51} testing BG-12 included a treatment arm with GA monotherapy. This was a multicenter, placebo-controlled, randomized trial involving 1,417 RRMS patients from 18 to 55 years of age, having an EDSS score up to 5.0, who had experienced at least one clinical relapse in the past year or showed one GdE brain lesion at baseline. Enrolled subjects were randomized either to BG-12 240 mg twice a day, BG-12 240 mg three times a day, GA 20 mg SC daily, or placebo, and were treated for 2 years. Compared to placebo, relapse risk was reduced by 29%, 34%, and 45% by GA (\(P=0.01\)), twice-daily (\(P=0.002\)) and three-times-daily (\(P<0.001\)) BG-12, respectively (primary end point). Secondary end points, including disability progression and several radiological surrogates of disease activity, showed consistent results. Although the study was not powered to test the superiority or inferiority of BG-12 versus GA, both BG-12 doses were associated with results numerically similar or superior to GA across all study end points. A post hoc analysis with direct comparisons indicated a trend of superiority of BG-12 over GA (ARR – twice-daily BG-12 versus GA, \(P=0.10\), thrice-daily BG-12 versus GA, \(P=0.02\); new or enlarging T2 lesions – twice-daily BG-12 versus GA, \(P=0.007\), thrice-daily BG-12 versus GA, \(P=0.002\)). The limitations of this study were the partial blinding to treatment assignment, the late modification of the trial design with the inclusion of an additional comparative arm with GA required by healthy authorities, and the insufficient power for assessing direct efficacy comparisons between GA and BG-12.

In conclusion, three head-to-head trials showed comparable efficacy between GA and high-dose IFN\(\text{b}\)s in the treatment of RRMS, both from a clinical and radiological perspective. Notably, some results suggest that GA better protects against brain-volume loss, while high dose IFN\(\text{b}\)s are associated with fewer GdE lesions.

Evidence for neuroprotection from clinical trials

Besides preventing new MS-lesion formation, treatment with GA was also found to reduce the accumulation of
permanent black holes, namely persistently hypointense T2 lesions, which are indicative of irreversible tissue damage and correlate with disability.20 Indeed, compared to placebo, the proportion of new T2 lesions that evolved into chronic black holes in RRMS patients participating in the European/Canadian trial12 was statistically significantly lower (18.9% versus 26.3%, P=0.04). However, it should be stressed that under GA treatment, a similar (BEYOND trial, IFNβ 21.6% versus GA 23.5%; P>0.20)13 or smaller (BECOME trial, IFNβ 9.8% versus GA 15.2%; P=0.20)4 proportion of acute black holes turned into persistent black holes compared to IFNβ.

MS is characterized by a more rapid rate of brain-volume decrease compared to the general population, which argues in favor of a mechanism of neurodegeneration behind the disease. In an MRI subgroup analysis of the pivotal trial by Johnson et al,39 GA significantly reduced the loss of brain volume compared to placebo (mean annual brain-volume change: -0.6% and -1.8%, respectively; P=0.0078).35 This finding was, however, not confirmed by the European/Canadian trial.36 Notably, the REGARD study48 showed that GA better protects from brain-volume loss, while high-dose IFNβ is associated with fewer GdE lesions, which might support a neuroprotective property of GA partially independent of anti-inflammatory activity.

The integrity of axons in MS can be assessed in vivo by assessing levels of N-acetylaspartate, a neuronal marker compound.56 A spectroscopy analysis of a subgroup of 34 subjects participating in the Phase III PreCISe trial23 showed that treatment with GA was associated with an improvement, whereas placebo was associated with a decline in brain neuroaxonal integrity, as indicated by an increase and decrease in the ratio between N-acetylaspartate and creatine, respectively.56

In conclusion, several clinical studies suggest a possible neuroprotective effect of GA in MS. However, it has not yet been clarified if this effect is peculiar to GA or a general consequence of any efficacious anti-inflammatory compound.

High-dose GA and different regimens

GA is currently approved as a 20 mg daily SC injection. However, some experimental data have suggested that higher doses were associated with greater efficacy.57

High-dose GA

A Phase II clinical trial was performed to evaluate differences in efficacy, safety, and tolerability between 40 mg and 20 mg daily doses of SC GA in 38 RRMS patients for 9 months.58 The primary efficacy end point was the total number of GdE lesions on MRI at 7, 8, and 9 months of follow-up. Results showed a trend for increased efficacy in the higher compared to the lower dose (number of GdE lesions 3.62 versus 2.26, respectively, rate ratio 0.62; P=0.09). The decrease in GdE lesions occurred earlier in the 40 mg group (from month 3) than in the 20 mg group. Safety profiles were comparable between the two doses, with a mild increase of local injection-site manifestations with the 40 mg dose. The main limitation of this trial was the small sample size.

A more recent Phase III, randomized, double-blind, parallel-group trial compared daily administration of SC 40 mg or 20 mg GA over 1 year.59 This study was conducted in 136 sites across 20 different countries worldwide. A total of 1,262 patients were screened and 1,155 (91.5%) randomized to receive single prefilled daily shots of either 20 or 40 mg GA for 12 months. The primary efficacy outcome was the relapse rate in the first year, while secondary outcomes included MRI efficacy parameters, such as the cumulative number of GdE lesions, the number of new T2 lesions at 12 months, and brain-volume changes. At 1 year, no differences were found in the primary end point (mean number of relapses 0.28 versus 0.27 for 20 mg and 40 mg doses, respectively; mean annualized number of relapses 0.33 versus 0.35, respectively). The decrease in mean number of GdE lesions at 3 months compared to baseline (frequent MRI cohort, n=234) was more evident in the 40 mg group (37.6% reduction, P=0.012) than in the 20 mg one (21.9% reduction, P=0.172). The percentage reduction in GdE lesions was consistently higher in the 40 mg than in the 20 mg group at 6, 9, and 12 months, results supported by similar findings in the entire study population at 12 months (0.68 in the 20 mg group versus 0.54 in the 40 mg group, -21%). The mean number of new T2 lesions and percentage brain-volume changes at month 12 were similar in both groups.

The tolerability profile was comparable between the two dose groups, and was similar to that observed in previous GA 20 mg trials. This first Phase III trial on GA with a 20 versus 40 mg daily dose comparison suggested no gain in efficacy with higher GA doses over a 12-month period. Nevertheless, the beneficial effect of GA 40 mg on MRI activity appeared to start earlier than in the 20 mg dose regimen.45 The main limitation of the study was the short duration.

In conclusion, these two trials did not demonstrate superior efficacy of daily double-dose GA compared to the approved 20 mg GA, thus excluding this as a possible strategy to increase GA efficacy in MS treatment. Importantly, these two trials highlighted that GA 40 mg administration was feasible, well tolerated, and associated with a side-effect profile similar to the approved 20 mg GA, and raised the idea
to redistribute weekly 20 mg GA doses, reducing the number of injections to improve treatment adherence.

**Low-frequency GA**

Two small randomized exploratory studies tested different administration regimens of GA 20 mg. Khan et al compared daily administration of GA 20 mg to GA 20 mg every other day in 30 treatment-naïve RRMS patients. After 2 years, no differences in relapse rate, disability progression, change in $T_2$ brain lesion volume, or GdE lesions between the two groups were reported. In another study, Khan et al compared continued daily GA 20 mg to a switch to GA 20 mg twice a week in 48 RRMS patients that had been treated with GA 20 mg daily for at least 1 year. After 2 years, relapse rate, EDSS scores, and several MRI parameters ($T_2$ lesions, GdE lesions, percentage of brain-volume change) were similar in the two groups. Notably, the overall tolerability profile was considerably higher in the group of patients receiving GA less frequently. The limitation of these trials was the small sample size not allowing definitive conclusions.

**Low-frequency high-dose GA**

The GALA (Glatiramer Acetate Low-frequency Administration) study group designed a randomized, placebo-controlled, parallel-group, Phase III trial aimed at evaluating the efficacy and safety of a less frequent GA-administration regimen in a larger sample size. This treatment schedule might provide a convenient frequency of injections while maintaining a similar weekly dose as the approved daily 20 mg regimen. This study included 142 sites across 17 countries, and enrolled a total of 1,404 RRMS patients. Out of these patients, 943 were randomized to GA 40 mg three times weekly and 461 to placebo three times weekly for 12 months.

An open-label phase in which all patients were invited to continue treatment with the same 40 mg GA thrice-weekly regimen is ongoing. A total of 1,219 patients were evaluable at 12 months (86.8%). Patients receiving GA 40 mg three times weekly demonstrated a significant reduction (34%) in ARR, which represented the primary end point of the study (mean ARR 0.331 and 0.505 in GA and placebo, respectively; $P<0.0001$).

In addition, the GA-treated group showed a longer time to relapse and a greater proportion of relapse-free patients. MRI parameters were also evaluated as secondary end points, and GA-treated patients showed a significant reduction at both 6 and 12 months in the cumulative number of GdE lesions and cumulative number of new or newly enlarging $T_2$ lesions compared to placebo. No significant differences were found in terms of brain volume.

The tolerability profile was consistent with that observed in trials testing the currently used 20 mg daily formulation. A major limitation of the trial was the absence of a third arm comparing the efficacy of GA 40 mg three times a week to GA 20 mg daily.

The ARR reduction observed in the GALA study (34%) is roughly in line with that reported in the pivotal trial (29%); however, populations in the two trials differed in baseline characteristics, reflecting more advanced and severe MS disease in the pivotal trial compared to the GALA trial. This is confirmed by the substantial difference in the absolute ARR reported in the two trials (placebo group – pivotal 0.84, GALA 0.505; GA group – pivotal 0.59, GALA 0.331), making indirect efficacy comparison unreliable.

In summary, the GALA study proved the efficacy of GA 40 mg three times weekly in reducing the ARR and MRI activity in RRMS patients over a 12-month period, with a safety profile that was comparable to that of the approved 20 mg daily dose. These results suggest that GA 40 mg three times weekly represents a valid alternative administration regimen for patients with poor needle tolerance who prefer a less frequent injection schedule. This treatment schedule was approved in the US in early 2014.

**Clinical safety**

GA’s safety profile in RRMS has been studied and confirmed by long-term studies up to 22 years and an experience with this drug of more than 1 million patient-years.

**Side-effect profile: GA 20 mg daily**

Side effects with GA are usually mild and well tolerated. Injection-site reactions (ISRs) have been reported as the most commonly complained-of adverse event, reported in around 80% of patients. ISRs consist of pain, itching, swelling, and redness, and are isolated or randomly associated. Some strategies have been proposed to reduce the incidence and severity of ISRs, such as warm compresses applied to the injection site 5 minutes before self-injection, which has been demonstrated to be effective.

Around 10% of GA-treated MS patients complain about an immediate postinjection reaction, which includes symptoms of flushing, chest pain, palpitations, anxiety, dyspnea, tachycardia, throat constriction, and urticaria. Immediate postinjection-reaction symptoms are usually transient and self-limited, requiring no specific treatment, but can be frightening when first experienced and surely influence adherence.

Around 2% of patients participating in GA-related clinical trials experienced localized lipoatrophy or other skin complications.
abnormalities,\textsuperscript{46} which might be disfiguring and sometimes become permanent. There is no known treatment for lipoatrophy, which has to be prevented by instructing patients in proper injection technique and advice to change injection sites daily.

**Side-effect profile: alternative treatment regimens**

Both daily and thrice-weekly GA 40 mg showed a side-effect profile comparable to low doses. In the GALA study,\textsuperscript{62} GA-treated patients experienced local adverse events, such as ISRs (35.2\% versus 5\% with placebo), 99.9\% of which were of mild or moderate intensity. These ISRs were most commonly represented by erythema, pruritus, or pain. The frequency of serious adverse events was similar between GA and placebo groups (approximately 4.5\% in each group). These severe episodes led to treatment discontinuation in 3.1\% of GA- and 1.3\% of placebo-treated patients.

**Long-term safety and drug interactions**

After decades of continuous use, no cumulative toxicities or late-emerging adverse events have been reported. No drug interactions are known for GA, and due to the absence of immunosuppressive effects, no increase of opportunistic infections or malignancies are associated with its use.\textsuperscript{39–42,44}

**Pregnancy and fertility**

GA is the only disease-modifying therapy with a US Food and Drug Administration (FDA) pregnancy category B rating, indicating no fetal risks in animal studies. However, due to the lack of adequate and well-controlled studies in human pregnancies, GA is currently advised to be stopped prior to an anticipated pregnancy or when pregnancy is recognized.\textsuperscript{65} Postmarketing surveillance data on GA-treated women showed a miscarriage rate of 17\%,\textsuperscript{66} comparable to the 10\%–15\% reported for the general population in the US.\textsuperscript{69} No apparent increased risks of adverse fetal or pregnancy outcomes were reported.\textsuperscript{68} Further published open-label observational studies on GA exposure during pregnancy (beyond the first trimester, in some cases throughout the entire pregnancy period) seem to confirm preclinical studies, and suggest that GA is not associated with teratogenicity or a higher rate of miscarriage.\textsuperscript{70–72} Lastly, GA has no reported effects on fertility, as shown in a multigeneration reproduction and fertility study in rats.\textsuperscript{73}

In conclusion, GA has an excellent safety profile both in the short and long (up to 22 years) term, and is the only MS immunomodulant therapy classified as FDA B category for pregnancy risk. It has no drug-to-drug interactions relevant to clinical practice. Its adverse-event profile includes mainly skin-related side effects and systemic reactions in a minority of patients.

**Adherence to GA treatment**

The lack of adherence over the long term represents one of the main causes for a suboptimal response to MS treatments.\textsuperscript{74} GA is an MS drug requiring a higher frequency of self-injections compared to other MS treatments, and adherence has been shown to be inversely proportional to the number of injections.\textsuperscript{75} Main barriers to proper adherence to GA include needle phobia and self-injection anxiety.\textsuperscript{74}

At the 15-year follow-up of the pivotal study by Johnson et al\textsuperscript{44} 43\% of the initially randomized subjects were still on GA treatment. With regard to a lower-frequency administration regimen, data in the head-to-head BEYOND study\textsuperscript{49} showed a similar proportion of dropouts in the GA group (16\%) as the other two treatment groups receiving IFNβ-1a 250 μg (12\%) or 500 μg (18\%), despite the higher frequency of SC injection in the first group. Similar proportions were observed in the BECOME\textsuperscript{49} (GA 30\% versus IFNβ-1a 20\%) and REGARD\textsuperscript{48} (GA 14\% versus IFNβ-1a 21\%) trials. In an open-label observational study on a German cohort of 308 MS patients, GA showed a significantly lower discontinuation rate compared to IFNβ during 6 and 24 months of observation (8.9\% versus 32.9\%, respectively), due to the lower rate of systemic adverse events.\textsuperscript{76} On the other hand, a recent meta-analysis\textsuperscript{77} investigated adherence rates to disease-modifying treatments in MS: data for GA showed slightly lower adherence rates compared to IFNβ-1a intramuscularly once per week, IFNβ-1b SC every other day, and IFNβ-1a SC three times per week (56.8\%, 69.4\%, 63.8\%, and 58.4\% respectively).

In conclusion, adherence to standard-regimen GA treatment (20 mg daily) may be challenging, mainly due to the higher number of injections and slightly lower adverse events than other injected drugs. Reinforcing the importance to administer the treatment regularly is a key task for treating neurologists. Together with a good tolerability profile in the long term, newer and lower-frequency treatment regimens might improve patient adherence to therapy.

**Conclusion and future**

Decades after its approval, GA is still a well-established treatment option for RRMS and CIS. It is associated with good and sustained clinical efficacy, with approximately 30\%
reduction of the ARR, which is comparable to high-dose IFNs, and an optimal safety profile, even in the long term. All these data support its current use as a first-line treatment option for CIS and RRMS patients. GA could be electively considered as a treatment option particularly in some clinical conditions, such as polymorbid and/or polytreated patients, as it has no relevant drug-to-drug interactions, female patients planning a pregnancy (FDA pregnancy category B), and patients suffering from relevant fatigue, which can potentially be worsened by IFNβ side effects.

The main barrier to GA treatment is daily injections and consequent ISRs, with the risk of reduced adherence and therefore efficacy. More recent data have shown that high-dose GA (ie, 40 mg) given three times weekly is safe and well tolerated. Provided that similar efficacy between the two is reported, this new alternative administration regimen might largely substitute the standard one, with net advantage in terms of tolerability.

Acknowledgment
We thank Liliane Petriini (PhD) for writing assistance.

Author contributions
MC contributed to the drafting of the manuscript. GD contributed to the drafting of the manuscript and the preparation of the table. All authors made substantial contributions, critically revised the manuscript, and approve the final version.

Disclosure
CG has received personal compensation from Teva, Merck Serono, Biogen Idec, Bayer Schering, Novartis, and Genzyme. CZ has received personal compensation from Teva, Merck Serono, Biogen Idec, Bayer Schering, Novartis, and Genzyme. The other authors report no conflicts of interest in this work.

References


68. Coyle P, Johnson K, Pardo L. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Poster presented at: 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 17–20, 2003; Milan, Italy.